Opinion|Videos|November 16, 2026

Rethinking Testosterone Therapy After the FDA Label Revisions

Fact checked by: Hannah Clarke

Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.

Decades of fear about testosterone therapy rested on weak evidence, and the regulatory record is finally catching up with the science. Moderated by Dr. Amy Pearlman, this webinar brings together Dr. Abraham Morgentaler, Dr. Mohit Khera, and Dr. Helen Bernie, 3 members of the December 2025 FDA expert panel on testosterone therapy for men.

Related to this article